Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers

NCT03618953 is registered in ClinicalTrials.gov with Turnstone Biologics, Corp. as lead sponsor.

NCT NCT03618953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03618953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers
Lead sponsor
Turnstone Biologics, Corp.
Phase
Phase 1
Overall status
Terminated
Start date
June 21, 2018
Completion date
March 5, 2021
Enrollment
8 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-associated cancers